Waystar Targets Autonomous Revenue Cycle With AI, Automation Push at Investor Day

Waystar Holding Corp. (WAY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Waystar Reports Second Quarter 2026 Results Q2 revenue of $319.7M, up 18% YoY Q2 net income of $40.9M and non-GAAP net income of $83.3M Q2 net income margin of 13%; adjusted EBITDA margin of 43% Raising revenue and adjusted EBITDA guidance for 2026 LEHI, Utah and LOUISVILLE, Ky.,

Fitch Ratings upgraded Waystar Holding Corp. (NYSE:WAY) and Waystar Technologies’ Long-Term Issuer Default Rating to BB+ from BB, and raised the first lien term loan to BBB- (Recovery Rating RR2). Fitch cited lower leverage expectations, with Fitch-adjusted EBITDA leverage projected below 3.0x in fiscal 2026 and sustained under 3x, plus strong recurring revenue and FCF.

Novartis (NVS) and Ionis (IONS) announced that their heart drug, pelacarsen, failed in Phase 3 trials. Both companies' stocks declined in after-hours trading. The drug targets Lp(a), a cardiovascular marker not significantly affected by diet or exercise.

Mizuho identified Snowflake as its top pick in the software largecap sector, citing 37% year-over-year revenue growth and strong AI product demand. The company raised its fiscal year 2027 product revenue growth outlook to 36% and received multiple price target increases from other firms. Mizuho maintains an Outperform rating and raised its price target to $425.

Tesla began offering paid rides in its Cybercab, a fully autonomous vehicle without a steering wheel, designed for passenger transport. The Cybercab, produced in Austin, Texas, is not yet available to the general public. Tesla's stock, valued at $1.5 trillion, relies on its dominance in autonomous vehicle technology. Analysts note that a broader rollout could impact Tesla's stock performance. The company faces competition from Waymo and regulatory challenges.

Moderna's stock (MRNA) has pulled back from recent highs despite a 404% year-to-date gain. The company reported positive phase 3 trial results for its cancer vaccine, intismeran autogene, in collaboration with Merck. Analysts estimate potential peak revenue of $5.6 billion for the vaccine, shared equally with Merck. Moderna also gained FDA approval for its flu vaccine, mFLUSIVA. Despite a high valuation, the company's pipeline and clinical progress make it an attractive long-term investment, acc